# Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

> **NCT03799094** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Clifford Hospital, Guangzhou, China** · enrollment: 150 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Vitamin C
- **DRUG:** Tyrosine kinase inhibitor

## Key facts

- **NCT ID:** NCT03799094
- **Lead sponsor:** Clifford Hospital, Guangzhou, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-05
- **Primary completion:** 2020-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03799094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03799094, "Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03799094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*